The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease

Experimental Gerontology

Volumn 40, Issue 3, 2005, Pages 157-163

  Obermayr, Rudolf P ^a   Mayerhofer, Lothar ^a   Knechtelsdorfer, Maarten ^a   Mersich, Nicole ^a   Huber, Erik R ^a   Geyer, Georg ^b   Tragl, Karl Heinz ^a  

^a DANUBE HOSPITAL   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acetylcholinesterase inhibitor; Donepezil; Elderly male; GHRH test; Growth hormone; Insulin like growth factor 1; Somatopause

Indexed keywords

DONEPEZIL; GROWTH HORMONE; PLACEBO; SOMATOMEDIN C;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG EFFECT; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 14844330077     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2004.11.001     Document Type: Article

References (58)

1. A.A. Abbasi, D.E. Mattson, E.H. Duthie Jr., C. Wilson, L. Sheldahl, E. Sasse, and I.W. Rudman Predictors of lean body mass and total adipose mass in community-dwelling elderly men and women Am. J. Med. Sci. 315 1998 188 193
2. A. Aleman, H.J. Verhaar, E.H. De Haan, W.R. De Vries, M.M. Samson, M.L. Drent, E.A. Van der Veen, and H.P. Koppeschaar Insulin-like growth factor-I and cognitive function in healthy older men J. Clin. Endocrinol. Metab. 84 1999 471 475
3. E. Arvat, M. Cappa, F.F. Casanueva, C. Dieguez, E. Ghigo, M. Nicolosi, R. Valcavi, and M. Zini Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women J. Clin. Endocrinol. Metab. 76 1993 374 377
4. H. Bando, C. Zhang, Y. Takada, R. Yamasaki, and S. Saito Impaired secretion of growth hormone-releasing hormone, growth hormone and IGF-1 in elderly men Acta Endocrinol. (Copenh.) 124 1991 31 36
5. M.R. Blackman, J.D. Sorkin, T. Munzer, M.F. Bellantoni, J. Busby-Whitehead, T.E. Stevens, J. Jayme, K.G. O'Connor, C. Christmas, J.D. Tobin, K.J. Stewart, E. Cottrell, C. St Clair, K.M. Pabst, and S.M. Harmann Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial JAMA 288 2002 2282 2292
6. N.D. Borofsky, J.H. Vogelman, R.A. Krajcik, and N. Orentreich Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies Clin. Chem. 48 2002 2248 2251
7. E. Carro, J.L. Trejo, T. Gomez-Isla, D. LeRoth, and I. Torres-Aleman Serum insulin-like growth factor 1 regulates brain amyloid-β levels Nat. Med. 12 2002 1390 1397
8. V. Coiro, R. Volpi, P. Bertoni, G. Finzi, A. Marcato, A. Caiazza, R. Colla, R. Giacalone, G. Rossi, and P. Chiodera Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men Gerontology 38 1992 217 222
9. H. de Boer, G.J. Blok, C. Popp-Snijders, L. Stuurman, R.C. Baxter, and E. van der Veen Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers J. Clin. Endocrinol Metab. 81 1996 1371 1377
10. S. Doré, S. Kar, W.H. Zheng, and R. Quirion Rediscovering good old friend IGF-1 in the new millenium: possible usefulness in Alzheimer's disease and stroke Pharm. Acta Helv. 74 2000 273 280
11. K. Friend, A. Iranmanesh, I.S. Login, and J.D. Veldhuis Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half life, basal GH secretion or the orderliness of GH release Eur. J. Endocrinol. 137 1997 377 386
12. J. Frystyk Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis Growth Horm. IGF Res. 14 2004 337 375
13. E. Ghigo, S. Goffi, E. Arvat, M. Nicolosi, M. Procopio, J. Bellone, E. Imperiale, A. Mazza, G. Baracchi, and F. Capanni Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging Acta Endocrinol. (Copenh.) 123 1990 169 173
14. D. Goodman-Gruen, and E. Barrett-Connor Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study Am. J. Epidemiol. 145 1997 970 976
15. M. Hameed, K.H.W. Lange, J.L. Andersen, P. Schjerling, M. Kjaer, S.D.R. Harridge, and G. Goldspink The effect of recombinant human growth hormone and resistance training on IGF-1 mRNA expression in the muscles of elderly men J. Physiol. 555 2003 231 240
16. S.M. Harmann, and M.R. Blackman Use of growth hormone for prevention or treatment of effects of aging J. Gerontol. A Biol. Sci. Med. Sci. 59 2004 652 658
17. J.V. Hennesy, J.A. Chromiak, S. Della Ventura, S.E. Reinert, J. Puhl, D.P. Kiel, C.J. Rosen, H. Vandenbourgh, and D.B. MacLean Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people J. Am. Geriatr. Soc. 49 2001 852 858
18. A. Irnmanesh, G. Lizarralde, and J.D. Veldhuis Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts and half live of endogenous GH in healthy men J. Clin. Endocrinol. Metab. 73 1991 1081 1088
19. J.A. Janssen, H. Burger, R.P. Stolk, D.E. Grobbee, F.H. de Jong, S.W. Lamberts, and H.A. Pols Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women Eur. J. Endocrinol. 138 1998 627 632
20. A. Juul, T. Scheike, M. Davidsen, J. Gyllenborg, and T. Jorgensen Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study Circulation 106 2002 939 944
21. V. Kaasinen, K. Nagren, T. Jarvenpaa, A. Roivainen, M. Yu, V. Oikonen, T. Kurki, and J.O. Rinne Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease J. Clin. Psychopharmacol. 22 2002 615 620
22. E. Kajantie, C.H. Fall, M. Seppala, R. Koistinen, L. Dunkel, H. Yilharsila, C. Osmond, S. Andersson, D.J. Barker, T. Forsen, R.I. Holt, D.I. Philips, and J. Eriksson Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-1 in elderly people: relationships with cardiovascular risk factors, body composition, size at birth, and childhood growth J. Clin. Endocrinol. Metab. 88 2003 1059 1065
23. M. Kelijman Age-related alterations of the growth hormone/insulin-like growth factor-1 axis J. Am. Geriatr. Soc. 39 1991 295 307
24. J.S. Kennedy, R.J. Polinsky, B. Johnson, P. Loosen, A. Enz, R. Laplanche, D. Schmidt, L.C. Mancione, W.C. Parris, and M.H. Ebert Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans J. Clin. Psychopharmacol. 19 1999 513 521
25. I. Lang, G. Schernthaner, G. Pietschmann, R. Kurz, J.M. Stephenson, and H. Templ Effects of sex and age on growth hormone response to growth hormone-releasing hormone in healthy individuals J. Clin. Endocrinol. Metab. 65 1987 535 540
26. G.A. Laughlin, E. Barrett-Connor, M.H. Criqui, and D. Kritz-Silverstein The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study J. Clin. Endocrinol. Metab. 89 2004 114 120
27. D.R. Liston, J.A. Nielsen, A. Villalobos, D. Chapin, S.B. Jones, S.T. Hubbard, I.A. Shalaby, A. Ramirez, D. Nason, and W.F. White Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease Eur. J. Pharmacol. 486 2004 9 17
28. J. Manetta, J.F. Brun, L. Maimoun, A. Callis, C. Prefaut, and J. Mercier Effect of training on the GH/IGF-1 axis during exercise in middle aged men: relationship to glucose homeostasis Am. J. Physiol. Endocrinol. Metab. 28 2002 E929 E936
29. F. Martin Frailty and the somatopause Growth Horm. IGF Res. 9 1999 3 10
30. F.C. Martin, A.L. Yeo, and P.H. Sonsken Growth hormone secretion in the elderly: aging and the somatopause Baillières Clin. Endocrinol. Metab. 11 1997 223 250
31. F. Massara, E. Ghigo, P. Molinatti, E. Mazza, V. Locatelli, E.E. Muller, and F. Camanni Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone-releasing factor in man Acta Endocrinol. (Copenh.) 113 1986 12 16
32. R. Mayeux, and M. Sano Treatment of Alzheimer's disease N. Engl. J. Med. 341 1999 1670 1679
33. N.R. Musolino, M.B. Da Cunha Neto, R. Marino Junior, D. Gianella-Neto, and M.D. Bronstein Evaluation of free insulin-like growth factor-I measurement on the diagnosis and follow-up treatment of growth hormone-deficient adult patients Clin. Endocrinol. (Oxf.) 50 1999 441 449
34. S. Nakamura, M. Mizuno, H. Katakami, A.C. Gore, and E. Teresawa Aging-related changes in in-vivo release of growth hormone-releasing hormone and somatostatin from the salk-median eminence in female rhesus monkeys (Macaca mulatta) J. Clin. Endocrinol. Metab. 88 2003 827 833
35. R.P. Obermayr, L. Mayerhofer, M. Knechtelsdorfer, K.H. Tragl, and G. Geyer The reduced release of GH by GHRH in 8 subjects aged 65-69 years is augmented considerably by rivastigmine, a drug for Alzheimer's disease Gerontology 49 2003 191 195
36. J. Oscarsson, G. Johannsson, J.O. Johannsson, P.A. Lundberg, G. Lindstedt, and B.A. Bengtsson Diurnal variation in serum insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations during daily subcutaneous injections of recombinant human growth hormone in GH-deficient adults Clin. Endocrinol. (Oxf.) 46 1997 63 68
37. A. Penalva, C. Muruais, F.F. Casanueva, and C. Dieguez Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone releasing hormone induced GH secretion in mormal subjects J. Clin. Endocrinol. Metab. 70 1990 324 329
38. M. Pollak Insulin-like growth factor physiology and cancer risk Eur. J. Cancer 36 2000 1224 1228
39. A.G. Renehan, M. Zwahlen, C. Minder, S.T. O'Dwyer, S.M. Shalet, and M. Egger Insulin-like growth factor (IGF-1), IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis Lancet 363 2004 1346 1353
40. S.L. Rogers, R.S. Doody, R.D. Pratt, and J.R. Ieni Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study Eur. Neuropharmacol. 10 2000 195 203
41. D. Rudman, M.H. Kutner, C.M. Rogers, M.F. Lubin, G.A. Fleming, and R.P. Brain Impaired growth hormone secretion in the adult population: relation to age and adiposity J. Clin. Invest. 67 1981 1361 1369
42. M. Russell-Aulet, C.A. Jaffe, R. Demott-Friberg, and A.L. Barkan In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: evidence for relative GHRH deficiency in aging J. Clin. Endocrinol. Metab. 84 1999 3490 3497
43. C. Scali, F. Casamenti, A. Bellucci, C. Costagli, B. Schmidt, and G. Pepeu Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats J. Neural Transm. 109 2002 1067 1080
44. S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B. D'Agostino, P.W. Wilson, and P.A. Wolf Plasma homocysteine as a risk factor for dementia and Alzheimer's disease N. Engl. J. Med. 346 2002 476 483
45. G. Sesmilo, B.M. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibansky Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial J. Clin. Endocrinol. Metab. 86 2001 1518 1524
46. T. Shibasaki, K. Shizume, M. Nakahara, A. Masuda, K. Jibiki, H. Demura, I. Wakabayashi, and N. Ling Age-related changes in plasma growth hormone response to growth hormone-releasing factor in men J. Clin. Endocrinol. Metab. 58 1984 212 214
47. M. Shigeta, and A. Homma Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles CNS Drug Rev. 7 2001 353 368
48. P. Sonsken Growth hormone and the somatopause Growth Horm. IGF Res. 9 1999 1 2
49. H. Sugimoto, H. Ogura, Y. Arai Limura, and Y. Yamanishi Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor Jpn. J. Pharmacol. 89 2002 7 20
50. J.L. Trejo, E. Carro, E. Garcia-Galloway, and I. Torres-Aleman Role of insulin -like growth factor-1 signaling in neurodegenerative disease J. Mol. Med. 82 2004 156 162
51. A.L. Unden, S. Elofsson, S. Knox, M.S. Lewitt, and K. Brismar IGF-I in a normal population: relation to psychosocial factors Clin. Endocrinol. (Oxf.) 57 2002 793 803
52. M.L. Vance Can growth hormone prevent aging? N. Engl. J. Med. 348 2003 779 780
53. J.D. Veldhuis, A. Iranmanesh, and A. Weltman Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans Endocrine 7 1997 41 48
54. A. Vermeulen Nyctohemoral growth hormone profiles in young and aged men: correlations with somatomedin-C levels J. Clin. Endocrinol. Metab. 64 1987 884 888
55. D.L. Waters, C.L. Yau, G.D. Montoya, and R.N. Baumgartner Serum sex hormones, IGF-1, and IGFBP3 exert a sexually dimorphic effect on lean body mass in aging J. Gerontol. A Biol. Sci. Med.Sci. 58 2003 648 652
56. A.J.J. Wood Growth hormone therapy in adults and children N. Engl. J. Med. 341 1999 1206 1216
57. A.J.J. Wood Alzheimer's disease N. Engl. J. Med. 351 2004 56 67
58. H. Yu, and T. Rohan Role of the insulin-like growth factor family in cancer development and progression J. Natl Cancer Inst. 93 2000 238